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Background: We aimed to comprehensively evaluate lipoprotein profile including lipid particle size following a
lifestyle intervention in metabolic syndrome (MetS) volunteers and to assess the associations between lipoprotein
subfractions and carotid-intima-media-thickness (CIMT) – a surrogate indicator of atherogenesis.
Methods: 100 participants (50–70 years) from the RESOLVE trial, underwent a one-year follow-up beginning with a
three-week residential program combining high exercise volume (15-20 h/week), restrictive diet (-500 kcal/day), and
education. For baseline references, 40 aged-matched healthy controls were recruited. Independent associations
between subfractions of lipoproteins and CIMT were evaluated using a generalized estimating equations model
accounting for variation in correlations between repeated measures. The lipoprotein subfractions profile was
assessed using Lipoprint® electrophoresis allowing to separate: the very low-density lipoprotein (VLDL) fraction, then
the intermediate-density lipoprotein (IDL) C, B and A, the low-density lipoprotein (LDL) with subfractions 1 and 2 as
large LDL and subfractions 3 to 7 as small dense LDL (sdLDL), and the high density lipoprotein (HDL) subfractions
categorized into large, intermediate, and small HDL. Apolipoproteins A1 and B were also measured.
Results: 78 participants completed the program. At baseline, apolipoproteins B/A1, VLDL, sdLDL and small HDL were
higher in MetS than in healthy controls; IDL, LDL size, large and intermediate HDL were lower. Despite time-related
regains during the follow-up, lipoprotein subfractions traditionally involved in cardiovascular risk, such as sdLDL,
improved immediately after the residential program with values closest to those of healthy controls. CIMT improved
throughout the lifestyle intervention. Using a generalized estimating equations model, none of the subfractions of
lipoproteins nor apolipoproteins were linked to CIMT.
Conclusions: Lipoprotein subfractions traditionally involved in CVR, decreased after the 3-week residential program.
During a 12 month follow-up, the time-related regains remained closer to the values of healthy controls than they
were at baseline. CIMT improved throughout the lifestyle intervention. However, we failed to demonstrate a link
between some lipoprotein subfractions and the atherogenicity directly measured from the wall thickness of arteries
(CIMT). Further investigations are required to explore the atherogenicity of lipoprotein subfractions.
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Cardiovascular disease is the main cause of morbidity
and mortality in individuals with metabolic syndrome
(MetS) [1]. Cardiovascular disease risk factors (CVR) in-
clude an excess of body fat, promoting dyslipidemia,
with reduced high-density lipoprotein cholesterol (HDL)
and increased low-density lipoprotein cholesterol (LDL)
[2]. A low level of HDL is regarded as a sensitive dis-
criminator of atherogenicity and is one among the five
criteria selected by the International Diabetes Federation
(IDF) to characterize MetS [3]. More specifically, lipo-
proteins can be differentiated into subfractions using
electrophoresis. LDL was categorized into subfractions 1
to 7, relative to decreasing size and increasing density.
Among them, the small dense subfractions 3 to 7
(sdLDL), not routinely assessed in clinical practice, are
presumed to be more atherogenic than larger LDL parti-
cles [4,5]. The notion of HDL functionality was more re-
cently introduced, with an increased CVR associated
with a decreased HDL size [6-8]. Relationships also
emerged between atherogenesis and other lipoproteins
classes, very low-density lipoprotein (VLDL) [9] and
intermediate-density lipoprotein (IDL) [10]. Moreover,
apolipoproteins (Apo) are the structural protein consti-
tuting the lipoproteins [11]. The atherogenicity of MetS
is possibly mediated by elevated ApoB [12], with the
proatherogenic/antiatherogenic ratio ApoB/ApoA1 being
strongly linked to CVR [11]. The relationship between
lipoprotein profiles and atherogenesis has a strong clin-
ical focus. Early detection of CVR may prevent a later
diagnosis of cardiovascular disease by using strategies
such as lifestyle interventions [13,14]. The Framingham
score [15], although commonly used to estimate the
CVR, may not permit the early risk detection available
from profiling the lipoprotein subfractions.
However, 1) previous studies that assessed the relation-
ship between CVR and some subfractions of lipoproteins
were mainly cross-sectional [16-20], 2) the role of each
subfractions is debated [21]. Even for the more robust the-
ory on atherogenicity of sdLDL, a predominance of very
large rather than sdLDL has been reported with increased
CVR [22], 3) The few studies reporting longitudinal
changes of lipoprotein subfractions following a lifestyle
intervention (diet, physical activity) describe relatively
acute [23] or short term responses [13,24-26], 4) lack direct
measures of atherogenicity inside the walls or arteries
[13,23-26], 5) provide limited selections of lipopro-
tein subfractions [13,23-26], and 6) are not reported
in populations with MetS [13,23-26].
Therefore, we aimed to describe long-term changes
in the profile of the lipoprotein subfractions among
metabolic syndrome volunteers from the RESOLVE trial
[27] who participated in a lifestyle intervention (diet and
physical activity). A secondary aim was to assess theassociations between lipoprotein subfractions and carotid-




One hundred participants (43 males, 57 females, mean
age 59.4 ± 5.0 years, 91.4 ± 12.9 kg, body mass index
(BMI) 33.4 ± 4.1 kg/m2) with MetS were recruited into this
one-year study commencing with a three-week residential
program. At baseline, blood levels were 5.5 ± 1.5 mmol/l
for glucose, 6.3 ± 0.8% for HbA1c, and 140.3 ± 14.2 mmHg
for systolic and 84.1 ± 9.7 mmHg for diastolic blood
pressure. Seventy-eight completed the whole intervention
[27]. Participants who dropped out of the program and
those who completed had similar baseline characteristics
with similar cardiovascular risk profiles. The mean com-
pliance scores regarding diet and exercise during the at-
home follow-up were 61.7 ± 24.3% between the 21st day
(D20) and the 3rd month (M3), 52.8 ± 24.31% between
M3 and the 6th month (M6), and 49.1 ± 23.5% between
M6 and the 12th month (M12). The intervention had posi-
tive effects on weight (-3.5 ± 0.2 kg at D20, -6.8 ± 0.4 kg at
M3, -6.7 ± 0.7 kg at M6, and -6.0 ± 0.8 kg at M12, from
baseline) and on weight-related changes [27]. The matched
healthy control group was composed of 26 males and
24 females with mean age of 58.0 ± 4.7 years and BMI of
22.4 ± 6.5 kg/m2.
Lipoprotein subfractions
Baseline
At baseline, individuals with MetS differed significantly
from their matched healthy controls in all subfractions
of lipoproteins and apolipoproteins with the exception
of large LDL. Specifically, ApoB/A1, VLDL, sdLDL and
small HDL were higher in MetS than in healthy controls;
IDL, LDL size, large and intermediate HDL were lower
in MetS than in healthy controls (Figure 1).
Follow-up
The greatest time-related changes were observed at the
end of the residential program (D20) and a progressive
return to baseline values occurred during the at-home
follow-up for ApoB/A1, VLDL, IDL, Large and sdLDL,
and small HDL. Large HDL increased throughout the
study. Even if only ApoB/A1 and VLDL failed differ
from healthy values of controls at M12, LDL size, and
large and intermediate HDL were closer to values of
healthy controls at M12 than at baseline (Figure 1).
Secondary outcomes
CIMT and the Framingham score decreased, but
remained higher than baseline values of healthy controls
(Figure 2). Other general outcomes (clinical and biological
Figure 1 Apolipoprotein B/A1 ratio and other lipoproteins sub-fractions profile using quantimetrix Lipoprint™ system. The very low-density
lipoprotein (VLDL) fraction, then the intermediate-density lipoprotein (IDL), the low-density lipoprotein (LDL) size which can distinguish the large LDL
sub-fractions 1–2, non atherogenic, and the small dense LDL (sdLDL) sub-fractions 3–7, atherogenic, and the high-density lipoprotein (HDL) sub-fractions
(large, intermediate and small). *: p < .05; **: p < .01; ***: p < .001 between different time of measurements for MetS participants. ‡: p < .05; ‡‡: p < .01;
‡‡‡: p < .001 between MetS participants and controls.
Figure 2 Framingham score and carotid-intima-media thickness in patients with MetS undertaking a lifestyle intervention. *: p < .05;
**: p < .01; ***: p < .001 between different time of measurements for MetS participants. ‡‡‡: p < .001 between MetS participants and controls.
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the same pattern [27].
Correlations
CIMT was correlated with large HDL (r = -.142, p = .004)
and IDL (r = -.183, p < .001). The Framingham score was
correlated with large (r = -.253, p < .001) and intermediate
HDL (r = -.226, p < .001), VLDL (r = -.178, p < .001), IDL
(r = .315, p < .001), large (r = .360, p < .001) and sdLDL
(r = .127, p = .012).
The change in CIMT between M6 and D0 correlated
with changes in ApoB/A1 between M6 and D0 (r = -.265,
p = .018). Changes in the Framingham score between
M6 and D0 correlated with the changes in Large HDL
(r = -.343, p < .001) and intermediate HDL (r = -.222,
p = .031) between M6 and D0.
Multivariable analyses
Change over time in CIMT and Framingham score and the
impact of covariates on these changes were separately
modeled using a multivariable generalized estimating
equations model that also accounted for variation in the
correlation between the repeated measurements (Table 1).
The multivariable model that controlled for the variables
listed in Table 1 showed that only type 2 diabetes was in-
dependently associated with an increase in CIMT levels.
Similarly, there was a significant visit effect when con-
trolling for all variables listed in Table 1. The CIMT level
decreased for each visit (time of measurement = effect of
physical activity and diet). None of the subfractions of li-
poproteins nor apolipoproteins were linked to CIMT. On
the other hand, Framingham score increased with age,
type 2 diabetes, and ApoB and it decreased with ApoA1,
large HDL and Intermediate HDL.
Discussion
Principal findings
The major findings showed that lipoprotein subfractions
traditionally involved in CVR, such as sdLDL, were
markedly improved after the 3-week residential program.
Then, the time-related regains remained closer to the
values of healthy controls. CIMT improved throughout
the lifestyle intervention. However, we failed to dem-
onstrate a link between some lipoprotein subfractions
and the atherogenicity directly measured from the wall
thickness of arteries (CIMT).
Improvement and time related regain of lipoprotein
subfractions
Even with normal levels of total LDL, cross-sectional
studies historically showed a link between sdLDL and
CVR [16-20]. This link persisted independently of other
lipid parameters [4,28,29]. In our study, sdLDL dropped
at D20 reaching control values, and despite a subsequentregain, remained lower at M12 than at baseline. The
LDL size followed a similar pattern, which could pos-
sibly be related to the high volume and intensity of exer-
cise during the residential program [30,31]. Even if there
is some evidence to support the hypothesis that certain
forms of large LDL particles may be atherogenic [22],
our participants with MetS had the same values of large
LDL as the healthy controls at baseline and at the end of
the study. It can be noted that sdLDL and large LDL
followed the same change. HDL is commonly considered
as a protective agent against cardiovascular disease,
which explains why low levels of HDL are included
among the five components defining MetS [3]. However,
the screening of the HDL subclasses has added interest
to the notional importance of HDL functionality. The
favorable role of HDL must be limited to the large frac-
tions only, the small fractions having conversely a pe-
jorative role [6-8]. Our intervention also supported a
favorable result for HDL subfractions. Small HDL de-
creased, with again a marked transient drop at D20,
and large subclasses rose, strongly between D0 and
D20, and marginally from D20 to M12. Within other
lipoprotein subfractions, similar observations are made
for intermediate subclasses and VLDL in response to
physical activity and diet [13,32]. The improvement in
VLDL levels, classically elevated in MetS [33], seems to
be notable because of its contribution to endothelium
damages [34]. The proatherogenic/antiatherogenic ratio
ApoB/ApoA1 shows stronger links to MetS and may be
a better risk discriminator than the single proathero-
genic measurement (ApoB) [11]. Between baseline and
D20, MetS individuals reached the ApoB/A1 values of
the healthy controls. In this study we also describe for
the first time the long-term one-year changes in levels
of the whole lipoprotein subfractions in patients with
MetS [13,23-26].
Lipoprotein subfractions and atherogenicity
To contribute to the existing debate on subfractions and
atherogenicity [21], currently mainly based on cross-
sectional studies [16-20], we added a direct measure of
atherogenicity inside the walls or arteries [13,23-26] in
our long-term follow-up design. The CIMT is a direct
measure of atherogenesis [35], whereas the Framingham
score is a probability of a cardiovascular event estab-
lished from a cluster of indexes: age, smoking status,
type 2 diabetes, blood pressure, LDL and HDL-cholesterol
[15]. Despite observed improvements in the Framingham
score and carotid-intima-media-thickness, values failed to
reach the control group, but remained better than baseline.
The Framingham score decreased significantly from base-
line to M12, with a marked and transient drop at D20.
Overall, the improvement was gradual from baseline to
M6 for CIMT (data not collected at M12) with the
Table 1 Association of CIMT or Framingham score with lipoprotein subfractions: generalized estimating equations
multivariable analyses
Models with ApoA1 and ApoB
Outcome: CIMT Outcome: Framingham score
Variables Coefficient (95% CI) P-value Coefficient (95% CI) P-value
Age, continuous 0.00 (-0.00 – 0.00) 0.173 0.11 (0.07 – 0.16) <0.001
Body Mass Index, continuous 0.00 (-0.00 – 0.00) 0.441 0.05 (-0.00 – 0.11) 0.057
Diabetes Mellitus, yes 0.05 (0.02 – 0.08) 0.001 3.03 (2.52 – 3.54) <0.001
ApoA1, continuous -0.00 (-0.05 – 0.04) 0.959 -3.25 (-4.13 – -2.37) <0.001
ApoB, continuous 0.01 (-0.04 – 0.05) 0.754 6.139 (5.32 – 6.96) <0.001
Visit -0.01 (-0.02 – -0.00) 0.019 -0.07 (-0.20 – 0.06) 0.288
Models with individual lipoprotein subfractions (without ApoA1 or ApoB)
Age, continuous 0.00 (-0.00 – 0.00) 0.170 0.10 (0.06 – 0.15) <0.001
Body Mass Index, continuous 0.00 (0.01 – 0.00) 0.569 0.01 (-0.04 – 0.06) 0.718
Diabetes Mellitus, yes 0.05 (0.02 – 0.08) 0.002 2.94 (2.45 – 3.43) <0.001
VLDL -0.00 (-0.00 – 0.00) 0.942 0.01 (-0.02 – 0.32) 0.675
IDL-C -0.00 (-0.00 – 0.00) 0.163 0.03 (-0.01 – 0.07) 0.189
IDL-B 0.00 (-0.00 – 0.00) 0.193 0.02 (-0.03 – 0.07) 0.426
IDL-A -0.00 (-0.00 – 0.00) 0.827 0.05 (0.02 – 0.08) 0.002
Large LDL (1-2) 0.00 (-0.00 – 0.00) 0.442 0.036 (0.02 – 0.05) <0.001
Small dense LDL (3-7) 0.00 (-0.00 – 0.00) 0.962 -0.01 (-0.06 – 0.04) 0.764
Large HDL 0.00 (-0.00 – 0.00) 0.631 -0.10 (-0.16 – -0.05) <0.001
Intermediate HDL -0.00 (-0.01 – 0.00) 0.187 -0.13 (-0.19 – -0.07) <0.001
Small HDL 0.00 (-0.00 – 0.01) 0.497 -0.03 (-0.10 – 0.05) 0.484
Visit -0.01 (-0.02 – -0.00) 0.015 -0.08 (-0.21 – 0.05) 0.245
All models also controlled for sex, compliance, and exercise intensity type.
Significant data (p<.05) are highlighted in bold.
Dutheil et al. Lipids in Health and Disease 2014, 13:112 Page 5 of 9
http://www.lipidworld.com/content/13/1/112difference acutely significant by D20. Therefore, it is pos-
sible that the time-delayed changes in CIMT were due to
the anatomical nature of this marker which is less dynamic
and more structural (arterial wall) than other blood re-
lated changes. Conversely, the Framingham score reacted
quickly to changes in lifestyle and were mainly linked to
LDL and HDL cholesterol, based on the method of its
calculation.
In order to minimize the probability of false positives
which increased with the number of correlations, we ran
a multivariable generalized estimating equations model
that controlled for various confounders and also accounted
for variation in correlation between the repeated measures.
To verify our findings, we also modeled the Framingham
score. As expected, we found that ApoA1 and ApoB were
significantly associated with the Framingham score. ApoB
is the structural protein for the atherogenic lipoproteins
(VLDL, IDL and LDL) responsible for transporting lipid
from the liver and gut to peripheral tissues, and ApoA1
is the major structural protein for HDL, responsible for ex-
cess cholesterol in peripheral tissues carried back to the
liver for excretion [11]. Thus, results are tightly coherentsince they are based on the formula to calculate the
Framingham score. The strong links with type two dia-
betes demonstrated similar plausibility. Associations be-
tween CIMT, and type two diabetes are well established
[36]. However, we failed to demonstrate a link between
the lipoprotein subfractions and CIMT. Further investi-
gations are required to explore the atherogenicity of lipo-
protein subfractions.
Strengths and limitations
Our study presents some major strengths: run-in design;
community-based long term intervention; direct meas-
ure of atherogenicity inside the walls or arteries; descrip-
tion of changes in all lipoprotein subfractions; the use of
an appropriate model to assess the independent associa-
tions of each of the lipoprotein subfractions with CVR;
MetS participants; a large sample size; the originality is also
arisen because such training volumes (15–20 h/week) have
seldom been investigated in obesity over 12 months.
However, this study has some limitations. CIMT was
not measured at M12 for financial reasons. Other mech-
anistic cardiovascular measures assessing CVR are not
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http://www.lipidworld.com/content/13/1/112yet available. A group without physical activity could
have provided opportunities to distinguish the effects of
physical activity from the diet. Implementing our inter-
vention in health practice is costly and our high volume
training protocol (15 hours per week) may prove difficult
to comply with in usual practice.
Conclusion
In conclusion, lipoprotein subfractions traditionally in-
volved in CVR, decreased after the 3-week residential pro-
gram. During a 12 month follow-up, the time-related
regains remained closer to the values of healthy controls
than they were at baseline. CIMT improved throughout
the lifestyle intervention. However, we failed to demon-
strate a link between some lipoprotein subfractions and the
atherogenicity directly measured from the wall thickness
of arteries (CIMT). Further investigations are required
to explore the atherogenicity of lipoprotein subfractions.
Methods
Participants
The general methodology of RESOLVE has been de-
scribed previously [27]. Briefly, participants were eligible
if they were aged between 50 and 70 years, suffering
from MetS [3], living a sedentary lifestyle, stable body
weight and unchanged medical treatment over the previ-
ous 6 months, no hepatic, renal or psychiatric diseases,
nor cardiovascular or endocrine diseases except those
defining MetS, no use of medications known to alterFigure 3 Range of lipoproteins sub-fractions on the separating gel (A
quantimetrix Lipoprint™ system.body weight, no restricted diet in the previous year, and
able to complete a maximal exercise tolerance test. For
baseline references, aged-matched healthy controls were
recruited with no disease/medication and no parameter
of the MetS. All participants provided written informed
consent. The study received the approval from the ethics
committees of St Etienne’s University Hospital, France.
Baseline assessments
The lipoprotein subfractions profile was assessed using
Lipoprint® electrophoresis (Quantimetrix Inc., Redondo
Beach, California). This method is based on electro-
phoresis of lipid stained serum (Sudan black) in non-
denaturing gel gradient of polyacrylamide [37]. Different
subfractions were identified by their migration distance
(Figure 3). Each lipoprotein subfraction has a specific
electrophoretic mobility with the VLDL fraction at the
origin of the separating gel, then the IDL, the LDL, and
the HDL fraction at the end of the gel. The Lipoprint sys-
tem can identify 7 subfractions of LDL. The diameter of
the LDL particles at the cut-off point separating subfrac-
tions 1–2 (large and commonly less atherogenic) from
subfractions 3–7 (small dense and atherogenic) was 251 Å
[37]. Similarly, HDL subfractions can be categorized into
large, intermediate, and small subfractions [38]. The system
includes tube gels and proprietary data analysis software to
determine the subfraction concentrations based on area
under the curve [38]. Coefficient of variation (CV) varies
according to the level of lipoproteins. Intra- and interassay), with a normal profile (B) and a pathological profile (C), using
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9.40% for VLDL, 2.94 – 11.14% and 4.73 – 13.63% for IDL,
1.05 – 1.52% and 1.26 – 1.57% for LDL, and 1.87 – 2.84%
and 2.49 – 4.69% for total HDL. For more information,
please see the technical informations available on the
Lipoprint® Quantimetrix® website.
Fasting blood samples were drawn between 7.00 and
7.30 a.m., aliquoted and stored at -80°C until analyses.
Basic biological assays were performed in the biochemistry
laboratory of the University Hospital (Clermont-Ferrand,
France), including ApoA1 and ApoB.
Individual risk factor scores were summed to deter-
mine the 10-year absolute risk of cardiovascular disease
using Framingham score [15].
The common carotid artery structure was evaluated
using a high-resolution B-mode ultrasound (MyLab30,
Esaote SpA, Firenze, Italy) The CIMT was defined as
the distance from the leading edge of the lumen-intima
interface to the leading edge of the media-adventitia inter-
face of the far wall. The CIMT of the left CIMTs was mea-
sured automatically by dedicated software (MyLab desk
9.0, Esaote, Florence, Italy) according to the Mannheim
consensus [35].
Follow-up assessments
All baseline assessments were repeated at 21 days (D20),
3 months (M3), 6 months (M6) and 12 months (M12),
with the exception of the CIMT which was not mea-
sured at M12.
First stage of intervention: a 3-week residential program
Throughout the residential program, MetS participants
underwent a daily diet restriction (-500 kcal/day) with
protein accounting for 15 to 20% of the total energy in-
take (1.2 g/kg/day), lipids 30 to 35%, and carbohydrates the
remainder. Participants had to exercise using endurance
training (90 min daily: aquagym, cycling or walking) and
resistance training (90 min × four days a week). Resistance
training consisted of 8 exercises with free weights and trad-
itional muscle building equipment. Participants were coa-
ched individually, and heart rate was monitored by Polar™
S810. Participants also attended lectures dealing with
MetS, nutrition, cooking and exercise to support the sus-
tainability of their new lifestyle on returning home.
Second stage of intervention: a 1-year at-home follow-up
At the end of first stage of intervention (D20), MetS par-
ticipants were asked to maintain the lifestyle (diet and
physical activity) experienced during the residential pro-
gram, with follow-up at M3, M6 and M12. Dietary and
exercise practices during this period were assessed with
the use of a compliance score determined on the basis
of the number of food questionnaires returned and the
number of training sessions undertaken per week. Theoverall compliance score was the mean of these two
scores (nutrition and physical activity) [27].
Statistical analysis
Data are presented as mean ± SD. Statistical analyses
were performed using SPSS (v19, SPSS Inc., Chicago, IL,
USA) and Stata software (v12, Stata-Corp, Texas, USA).
Normality of distribution was assessed by the Shapiro-
Wilk test. The primary focus of the analyses was the
12-month change in lipoprotein subfractions’ serum levels.
Changes over time were tested by a one-way ANOVA with
repeated-measures, with the use of Bonferroni post-hoc
test. Correlation matrices between lipoprotein subfrac-
tions and CVR were constructed using the non paramet-
ric Spearman test. In order to minimize the probability of
false positives when numerous correlations are calcu-
lated, the independent associations of each of the lipo-
protein subfractions with CVR (Framingham score or
CIMT) were further assessed using a multivariable gener-
alized estimating equations model that controlled for age,
gender, body mass index, presence of diabetes, partici-
pant’s compliance and exercise intensity while accounting
for multiple correlations between the repeated measures.
The descriptive characteristics of those who dropped out
of the program were also summarized. We also per-
formed a descriptive statistical analysis for participants
who dropped out to compare their characteristics with
those who completed the program. Significance was set at
the p < .05 level.
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